Subrata Ghosh

Founder & CEO

What does it take to thrive in the ever-changing world of veterinary healthcare? It’s simple, It takes resilience, adaptability, and a partner who understands the challenges and opportunities of the industry.

However, veterinarians and animal care providers today, face crises which encompasses regulatory restrictions, export bans, competition from multinational companies and even pandemics like COVID-19. Hence, survival and timely access to critical resources are essential.

At the same time, the veterinary market is growing rapidly, driven by government initiatives, rising demand, and increased awareness of animal health. Opportunities abound in large animal care, poultry, aqua, and companion animals, particularly where vaccination programs and nutrition support can make a real impact.

By leading the veterinary industry in this landscape, Embryo Group provides innovative products, strong partnerships, and comprehensive solutions that support veterinarians, farmers, and pet owners. It tackles challenges directly, supplying essential medicines, protective gear, and disinfectants with robust operational and financial management.

Two Decades of Growth

Embryo Group began its journey back in 2006 with a vision to grow in the veterinary and animal health sector. In 2009, the company successfully entered the institutional business with 37 products, marking its first major milestone. By 2010, operations expanded into Jharkhand, and in 2013, Embryo Group started functioning as a C&F agent, broadening its distribution network.

In 2014, the Kalpataru Office was inaugurated, followed by the establishment of business relationships with Inox India and Virbac in 2015, and Cadila Healthcare (Zenex) in 2016. Later, the company launched its Aquaticaa business in 2017, expanding into the aqua sector. In 2018, the corporate office was inaugurated, further solidifying its operational base. In 2019, Embryo Group partnered with Himalaya Wellness Company to serve both large and small animals.

During the COVID-19 pandemic in 2020, the company successfully supplied medicines and essential materials. In 2021, it launched its canine care business, and by 2022, it achieved a target revenue of 32 crore. In 2023, it surpassed its targets and launched a new division, Ova International.

By 2024, the company owned six delivery vehicles to enhance logistics, and in 2025, it successfully achieved its yearly budget, reflecting consistent growth and expansion over nearly two decades.

Over the years, the company has aligned its operations with government initiatives like the Gokul Mission and focused on institutional business, partnering with 73–78 companies, including the American Breeding Systems (ABS) and INOX. Embryo Group played a key role in supplying artificial insemination materials, instruments, and equipment to the sector.

The company has also expanded into third-party manufacturing of surgical instruments, selling products across West Bengal, Sikkim, Bhutan, and parts of Bangladesh. In 2012, it entered the aqua business, collaborating with Hitech Pharma, generating annual revenues of 6–7 crore. In addition, the company also developed its own aqua products marketed by its team.

Following this, it established a veterinary pathological lab (Anitech Solutions) covering 3,000 square feet, staffed by four to five doctors, twelve numbers paravets to provide diagnostic services for pet owners, hospitals, large animal farms and Zoo animals.

Later, the company expanded into companion animal care through its division named Canine Care, and partnered with Serum Labs to launch Swallowdale, a 24x7 veterinary hospital. The company supplies canine and feline food, medicines, and vaccines.

Its corporate office in Calcutta houses 37 staff, with a 25,000-square-foot ISO 9001:2015 certified store supporting 30 employees. The companion animal segment operates from a 10,000-square-foot office with 65 staff. In total, 132 employees support the company’s operations.

Notably, the company was recognized by The Industry Outlook as the fastest-growing veterinary pharmaceutical company in 2017–2018. In total, the company emphasizes continuous efforts to improve animal health, maintaining a focus on high-quality services, advanced facilities, and consistent growth across its divisions.

Complete Care Solutions through Anitech Solutions

Embryo Group offers a full spectrum of veterinary solutions, including advanced diagnostics such as blood tests, RT-PCR, allergy testing, rabies screening, X-ray, USG, ECG, and CT scans.

In addition, the company offers C&F services and operates a 24x7 veterinary hospital as Swallow Dale. It also provides advanced diagnostic services, including CT scans for pets, and conducts a full range of veterinary pathological and diagnostic tests. These offerings position the company as a complete provider for both livestock and companion animal healthcare.

Precision & Progress

Embryo Group upholds the highest standards in veterinary healthcare, ensuring the safety, consistency, and efficacy of its products. Medicines from external suppliers meet their own rigorous testing and certification, while in-house products undergo thorough laboratory evaluation.

A network of 35-40 technical doctors supports the group in maintaining quality, and highly trained staff educates customers on proper product use. Notably, a well-established distribution network across West Bengal and surrounded state in Eastern India ensures timely delivery and monitoring, covering both institutional and trade partners.

In parallel, the company is establishing its own R&D facil­ities, expected within six to seven months, to complement its existing collaborations with third-party partners. Once opera­tional, the in-house R&D will strengthen the company’s ability to develop innovative, future-ready solutions and reinforce trusted relationships across the animal healthcare community.

The Path Ahead

Embryo Group strives to set industry standards in veterinary care, focusing on wild animal treatment, poultry, and high-quality services while aiming to raise its EBT from 15 percent to 19.5–20 percent. The company targets 3-4 percent of the market with a 110 crore budget for 2026–27 and is expanding infrastructure, including 24x7 hospitals for over 200 patients.

In total, the company ensures reliable services for all customers while fostering team growth. The Founder and CEO, Subrata Ghosh concludes by stating “Our long-term vision is to become the leading veterinary organization by 2030, through careful planning, consistent effort, and a commitment to excellence.”